Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Goldhirsch

Showing results (461-470 of 753) with videos related to

Pageof 76
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2006
Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)L Perey, R Paridaens, H Hawle, et al.
Breast Care (Basel, Switzerland)|August 3, 2018
Metronomic Chemotherapy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Phase II TrialEmilia Montagna, Vincenzo Bagnardi, Giuseppe Cancello, et al.
Breast (Edinburgh, Scotland)|February 2, 2010
Preoperative therapy with trastuzumab and oral vinorelbine (+/- endocrine therapy) in patients with HER2-positive breast cancerMonica Iorfida, Vincenzo Bagnardi, Alessandra Balduzzi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 5, 2005
Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancerO Pagani, C Sessa, F Nolè, et al.
Lancet (London, England)|February 12, 1994
Effect of systemic adjuvant treatment on first sites of breast cancer relapseA Goldhirsch, R D Gelber, K N Price, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 1994
The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-upM Castiglione-Gertsch, C Johnsen, A Goldhirsch, et al.
Israel Journal of Medical Sciences|February 1, 1995
The best available adjuvant treatments are within the framework of clinical trials. The International Breast Cancer Study GroupA Goldhirsch, R D Gelber, M Castiglione, et al.
Breast (Edinburgh, Scotland)|November 4, 2009
Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: a mono-institutional case-series reportE Munzone, A Di Pietro, A Goldhirsch, et al.
Breast (Edinburgh, Scotland)|August 21, 2013
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancerGiuseppe Curigliano, Xavier Pivot, Javer Cortés, et al.
Cancer Chemotherapy and Pharmacology|December 8, 2007
Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxelRosalba Torrisi, Alessandra Balduzzi, Raffaella Ghisini, et al.
Pageof 76

Showing results (461-470 of 753) with videos related to

Sort By:
Pageof 76
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2006
Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)L Perey, R Paridaens, H Hawle, et al.
Breast Care (Basel, Switzerland)|August 3, 2018
Metronomic Chemotherapy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Phase II TrialEmilia Montagna, Vincenzo Bagnardi, Giuseppe Cancello, et al.
Breast (Edinburgh, Scotland)|February 2, 2010
Preoperative therapy with trastuzumab and oral vinorelbine (+/- endocrine therapy) in patients with HER2-positive breast cancerMonica Iorfida, Vincenzo Bagnardi, Alessandra Balduzzi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 5, 2005
Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancerO Pagani, C Sessa, F Nolè, et al.
Lancet (London, England)|February 12, 1994
Effect of systemic adjuvant treatment on first sites of breast cancer relapseA Goldhirsch, R D Gelber, K N Price, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 1994
The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-upM Castiglione-Gertsch, C Johnsen, A Goldhirsch, et al.
Israel Journal of Medical Sciences|February 1, 1995
The best available adjuvant treatments are within the framework of clinical trials. The International Breast Cancer Study GroupA Goldhirsch, R D Gelber, M Castiglione, et al.
Breast (Edinburgh, Scotland)|November 4, 2009
Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: a mono-institutional case-series reportE Munzone, A Di Pietro, A Goldhirsch, et al.
Breast (Edinburgh, Scotland)|August 21, 2013
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancerGiuseppe Curigliano, Xavier Pivot, Javer Cortés, et al.
Cancer Chemotherapy and Pharmacology|December 8, 2007
Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxelRosalba Torrisi, Alessandra Balduzzi, Raffaella Ghisini, et al.
Pageof 76